A fixed-dose combination targeting two pathways of glucose control. Metformin decreases hepatic glucose production and improves insulin sensitivity, while Glimepiride, a sulfonylurea, stimulates pancreatic insulin secretion — together supporting more comprehensive blood sugar management.
Why ChooseGlucofix™-M?
A dual-pathway combination for patients needing more than single-agent glycemic control, in a single convenient tablet.
Last updated on 26 July 2026
This information is for reference only and is not a substitute for advice from a qualified doctor or pharmacist. Please consult your physician before use.
Cista Medicorp